Pharmacokinetic modeling of PSMA-targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer.
contrast-enhanced ultrasound
molecular imaging
nanobubbles
pharmacokinetic modeling
prostate cancer
Journal
Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
20
06
2022
received:
12
03
2022
accepted:
19
08
2022
pubmed:
2
9
2022
medline:
19
10
2022
entrez:
1
9
2022
Statut:
ppublish
Résumé
Contrast-enhanced ultrasound (CEUS) by injection of microbubbles (MBs) has shown promise as a cost-effective imaging modality for prostate cancer (PCa) detection. More recently, nanobubbles (NBs) have been proposed as novel ultrasound contrast agents. Unlike MBs, which are intravascular ultrasound contrast agents, the smaller diameter of NBs allows them to cross the vessel wall and target specific receptors on cancer cells such as the prostate-specific membrane antigen (PSMA). It has been demonstrated that PSMA-targeted NBs can bind to the receptors of PCa cells and show a prolonged retention effect in dual-tumor mice models. However, the analysis of the prolonged retention effect has so far been limited to qualitative or semi-quantitative approaches. This work introduces two pharmacokinetics models for quantitative analysis of time-intensity curves (TICs) obtained from the CEUS loops. The first model is based on describing the vascular input by the modified local density random walk (mLDRW) model and independently interprets TICs from each tumor lesion. Differently, the second model is based on the reference-tissue model, previously proposed in the context of nuclear imaging, and describes the binding kinetics of an indicator in a target tissue by using a reference tissue where binding does not occur. Our results show that four estimated parameters, β, These promising results encourage further quantitative analysis of targeted NBs for improved cancer diagnostics and characterization.
Identifiants
pubmed: 36049109
doi: 10.1002/mp.15962
pmc: PMC9588563
mid: NIHMS1833854
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6547-6559Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB028144
Pays : United States
Organisme : NIH HHS
ID : S10 OD021635
Pays : United States
Informations de copyright
© 2022 American Association of Physicists in Medicine.
Références
Eur Urol. 2008 Sep;54(3):581-8
pubmed: 18423977
Eur Radiol. 2008 Apr;18(4):707-15
pubmed: 17938936
IEEE Trans Med Imaging. 2011 Aug;30(8):1493-502
pubmed: 21402509
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Cereb Blood Flow Metab. 1996 Jan;16(1):42-52
pubmed: 8530554
Med Image Anal. 2017 Jan;35:610-619
pubmed: 27723564
Nanomedicine. 2020 Aug;28:102213
pubmed: 32348874
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Jul-Aug;7(4):593-608
pubmed: 25580914
BJU Int. 2012 Dec;110(11 Pt C):E794-808
pubmed: 22958524
Nanomedicine. 2017 Jan;13(1):59-67
pubmed: 27565686
Phys Med Biol. 2017 Mar 21;62(6):2449-2464
pubmed: 28240217
Rev Urol. 2006;8 Suppl 1:S29-37
pubmed: 17021624
Lancet Oncol. 2014 Oct;15(11):e484-92
pubmed: 25281467
Nat Commun. 2020 May 7;11(1):2238
pubmed: 32382089
Invest Radiol. 2017 Jul;52(7):419-427
pubmed: 28257340
Anticancer Res. 2019 Jun;39(6):3101-3110
pubmed: 31177155
Am J Mens Health. 2018 Nov;12(6):1807-1823
pubmed: 30203706
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
Br J Radiol. 2012 Nov;85 Spec No 1:S3-17
pubmed: 22844031
Nanotheranostics. 2022 Feb 14;6(3):270-285
pubmed: 35223380
Eur Urol. 2013 Dec;64(6):876-92
pubmed: 23787356
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
Eur Urol. 2020 Jan;77(1):78-94
pubmed: 31326219
Nanomedicine. 2017 Oct;13(7):2159-2168
pubmed: 28603079
IEEE Rev Biomed Eng. 2016;9:121-47
pubmed: 27337725
Ultrasound Med Biol. 2013 Nov;39(11):2137-46
pubmed: 23932272
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Sci Rep. 2021 Feb 25;11(1):4726
pubmed: 33633232
Invest Radiol. 2014 Aug;49(8):561-9
pubmed: 24691142
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Ultrasound Med Biol. 2019 Sep;45(9):2502-2514
pubmed: 31248638
Nanoscale. 2019 Sep 7;11(33):15647-15658
pubmed: 31408083
Neuroimage. 1996 Dec;4(3 Pt 1):153-8
pubmed: 9345505
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593